Status:
UNKNOWN
Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection
Lead Sponsor:
Yonsei University
Conditions:
Tumor Disease Including Colorectal Cancer
Head & Neck Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
1. Background Cetuximab (trade name Erbitux) is a murine-human chimeric monoclonal antibody to human epidermal growth factor receptor (EGFR). This drug has been used as a treatment for colorectal canc...
Detailed Description
* Acquisition of agreement Agreement, explanation, and consent form for study of human derived sample those that approved by the IRB are obtained from patients who prospectively voluntarily participat...
Eligibility Criteria
Inclusion
- Adult men and women over 18 years of age
- Patients scheduled for cetuximab administration according to standard treatment guidelines for the treatment of underlying tumor disease.
Exclusion
- Patients who did not consent to the study voluntarily after IRB approval
- Persons who are vulnerable (including persons with disabilities, lack of physician capacity, pregnant status, persons who are accommodated in facilities, etc.)
- Those who can not read and understand the agreement
Key Trial Info
Start Date :
November 4 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 3 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03485638
Start Date
November 4 2016
End Date
November 3 2020
Last Update
April 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University
Seoul, South Korea, 03722